DBV Technologies SA

For the period ended Dec 31, 2023. Filed Mar 7, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 7, 2024

DBVT$11.51+4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 15. Exhibits and Financial Statement Schedules

The financial statements schedules and exhibits filed as part of this Annual Report on Form 10-K are as follows:

(a)(1) Financial Statements

Reference is made to the financial statements included in Item 8 of Part II hereof.

(a)(2) Financial Statement Schedules

All other schedules are omitted because they are not required or the required information is included in the financial statements or notes thereto.

(a)(3) Exhibits

EXHIBIT INDEX

Incorporated by Reference
Exhibit	Description	Schedule/Form	File Number	Exhibit	File Date
3.1* · By-laws (status) of the registrant (English translation)
4.1	Form of Deposit Agreement	Form F-1/A	333-198870	4.1	10/15/14
4.2	Form of American Depositary Receipt	Form F-1/A	333-198870	4.1	10/15/14
4.3	Description of Registered Securities	Form 20-F	001-36697	2.3	03/20/20
4.4	Registration Rights Agreement, dated as of March 23, 2018, between the registrant, 667, L.P. and Baker Brothers Life Sciences, L.P.	Form 6-K	001-36697	4.1	03/23/18
4.5	Registration Rights Agreement, dated as of June 8, 2022, between the registrant and the Investors named therein.	Form 8-K	001-36697	10.2	06/13/22
4.6	Securities Purchase Agreement, dated as of June 8, 2022, between the registrant and the Subscribers named therein.	Form 8-K	001-36697	10.1	06/13/22
10.1	Office Lease between the registrant and GENERALI VIE, dated March 3, 2025 (English translation)	Form 20-F	001-36697	4.2	04/29/15
10.2*	Office Lease between the registrant and SCI DANTON MALAKOFF, dated October 2, 2023 (English translation)
10.3*	Lease Agreement between DBV Technologies Inc. and SIG 106 LLC, dated March 28, 2022
10.4	Assignment, Development and Co-Ownership Agreement among the registrant, L’Assistance Publique—Hopitaux de Paris and Université Paris Descartes, dated January 7, 2009 (English translation)	Form F-1	333-198870	10.2	09/22/14
10.5#	Development Collaboration and License Agreement between the registrant and NESTEC S.A., dated May 27, 2016	Form 20-F	001-36697	4.14	03/22/17
10.6#	Amendment to Development Collaboration and License Agreement between the registrant and NESTEC S.A., dated July 12, 208	Form 20-F	001-36697	4.5	04/01/19
10.7*	Letter Agreement Terminating Development Collaboration and License Agreement between registrant and Société des Produits Nestlé S.A. (f/k/a NESTEC S.A.), dated October 26, 2023
10.8†	Form of Indemnification Agreement between the registrant and each of its executive officers and directors	Form F-1/A	333-198870	10.3	10/15/14
10.9†	2013 and 2014 Share Option Plans (English translation)	Form F-1/A	333-198870	10.4	09/22/14

	Incorporated by Reference
Exhibit	Description	Schedule/Form	File Number	Exhibit	File Date
10.10†	2012, 2013 and 2014 Free Share Plans (English translation)	Form F-1/A	333-198870	10.5	09/22/14
10.11†	Summary of BSA	Form F-1	333-198870	10.6	09/22/14
10.12†	Summary of BSPCE	Form F-1	333-198870	10.7	09/22/14
10.13†	2015 Share Option Plan (English translation)	Form 20-F	001-36697	4.10	04/28/16
10.14†	2015 Free Share Plans (English translation)	Form 20-F	001-36697	4.11	04/28/16
10.15†	2016 Share Option Plan (English translation)	Form 20-F	001-36697	4.12	03/22/17
10.16†	2016 Free Share Plan (English translation)	Form 20-F	001-36697	4.13	03/22/17
10.17†	2017 Share Option Plan (English translation)	Form 20-F	001-36697	4.14	03/16/18
10.18†	2017 Free Share Plan (English translation)	Form 20-F	001-36697	4.15	03/16/18
10.19†	2018 Share Option Plan (English translation)	Form 20-F	001-36697	4.17	04/01/19
10.20†	2018 Free Share Plan (English translation)	Form 20-F	001-36697	4.18	04/01/19
10.21†	2019 Share Option Plan (English translation)	Form 20-F	001-36697	4.19	03/20/20
10.22†	2019 Free Share Plan (English translation)	Form 20-F	001-36697	4.20	03/20/20
10.23†	2020 Share Option Plan (English translation)	Form 10-K	001-36697	10.21	03/17/21
10.24†	2020 Free Share Plan (English translation)	Form 10-K	001-36697	10.22	03/17/21
10.25†	2021 Share Option Plan (English translation)	Form 10-K	001-36697	10.22	03/9/22
10.26†	2021 Free Share Plan (English translation)	Form 10-K	001-36697	10.23	03/9/22
10.27†	2022 Share Option Plan (English translation)	Form 10-K	001-36697	10.24	03/2/23
10.28†	2022 Free Share Plan (English translation)	Form 10-K	001-36697	10.25	03/2/23
10.29†	2023 Share Option Plan (English translation)	S-8	333-275662	99.3	11/20/23
10.30†	2023 Free Share Plan (English translation)	S-8	333-275662	99.2	11/20/23
10.31†	Executive Agreement, dated November 29, 2018, between the registration and Daniel Tassé	Form 10-K	001-36697	10.23	03/17/21
10.32†	First Amendment to the Executive Agreement of Daniel Tassé, dated June 27, 2019, between the registrant and Daniel Tassé	Form 10-K	001-36697	10.24	03/17/21
10.33†	Executive Agreement, dated July 22, 2019, between the registrant and Pharis Mohideen	Form 10-K	001-36697	10.25	03/17/21
10.34†	Letter Agreement, dated June 26, 2019, between the registrant and Sébastien Robitaille (English translation)	Form 10-K	001-36697	10.26	03/17/21
10.35†	Letter Agreement, dated December 1, 2020, between the registrant and Sébastien Robitaille (English translation)	Form 10-K	001-36697	10.27	03/17/21

		Incorporated by Reference
Exhibit	Description	Schedule/Form	File Number	Exhibit	File Date
10.36*†	English Summary Translation of Separation Agreement and Release between Sébastien Robitaille and registrant
10.37*†	Letter Agreement, dated November 1, 2023, between the registrant and Virginie Boucinha (English translation)
21.1*†	List of subsidiaries of the registrant
23.1*	Consent of Deloitte & Associés
23.2*	Consent of KPMG S.A.
24.1**	Power of Attorney (included on the signature page of this report).
31.1*	Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a- 14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a- 14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**	Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
97.1*	Incentive Compensation Recoupment Policy, approved
101.INS*	Inline XBRL Instance Document
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

*	Filed herewith.

Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act .of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

†	Indicates a management contract or any compensatory plan, contract or arrangement.

#	Confidential treatment has been granted from the Securities and Exchange Commission as to certain portions of this document

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.